PF-07934040 / Pfizer - LARVOL DELTA

Official website of the Center for Drug Evaluation of the China Medical Products Administration (CDE) showed that Pfizer's Class 1 new drug Pan-KRAS inhibitor PF-07934040 tablets was approved for clinical use in China [Google translation] (bydrug.pharmcube.com) - "Overseas, Pfizer is conducting a Phase I clinical trial (NCT06447662) on PF-07934040 to evaluate the efficacy and safety of PF-07934040 alone or in combination with other targeted drugs in the treatment of advanced solid tumors (non-small cell lung cancer, colorectal cancer, pancreatic cancer) with KRAS gene mutations. The study plans to enroll 330 subjects, and the main indicators are expected to be completed in July 2027."

New trial • Trial status • Colorectal Cancer • Non Small Cell Lung Cancer • Pancreatic Cancer